A Double-blind, Randomized, Placebo-controlled, Multicenter Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)
A Double-blind, Randomized, Placebo-controlled, Multicenter Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)
The objective of this study is to evaluate and compare efficacy of 3 dose levels of PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic Lupus Erythematosus (SLE) Responder Index. The study will evaluate secondary and exploratory measures as well.
Inclusion Criteria:
Exclusion Criteria:
Gainesville, Florida 32607, United States
Boston, Massachusetts 02111, United States
Chapel Hill, North Carolina 27514, United States
Chapel Hill, North Carolina 27514, United States
C.a.b.a, C1431FWO, Argentina
San Juan, J5402DIL, Argentina
Barranquilla, Atlántico, Colombia
Bogota, Cundinamarca, Colombia
Bogota, Cundinamarca, Colombia
Gyula, 5700, Hungary
Elblag, 82-300, Poland
Taipei TOC, 100, Taiwan